Carboxyamidotriazole inhibits cell growth of imatinib-resistant chronic myeloid leukaemia cells including T315I Bcr-Abl mutant by a redox-mediated mechanism

Cancer Letters

Volumn 300, Issue 2, 2011, Pages 205-214

  Corrado, Chiara ^a   Raimondo, Stefania ^a   Flugy, Anna Maria ^a   Fontana, Simona ^a   Santoro, Alessandra ^b   Stassi, Giorgio ^c   Marfia, Anna ^b   Iovino, Flora ^c   Arlinghaus, Ralph ^d   Kohn, Elise C ^e   Leo, Giacomo De ^a   Alessandro, Riccardo ^a  

^a Sezione di Biologia e Genetica   (Italy)

^b Dipartimento di Ricerca Clinica e Biotecnologia   (Italy)

^c Dipartimento di Scienze Chirurgiche ed Oncologiche   (Italy)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Carboxyamidotriazole (CAI); Chronic myelogenous leukemia (CML); Drug resistance; Reactive oxygen species (ROS)

Indexed keywords

5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; ABELSON KINASE; BREAKPOINT CLUSTER REGION PROTEIN; IMATINIB; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CALCIUM TRANSPORT; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WILD ANIMAL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MUTATION; OXIDATION-REDUCTION; PIPERAZINES; PYRIMIDINES; REACTIVE OXYGEN SPECIES; TRIAZOLES;

EID: 78649630618     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.10.007     Document Type: Article

References (43)

1. Ben-Neriah Y., Daley G., Mes-Masson A., Witte O., Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 1986, 233:212-214.
2. Rowley J. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973, 243:290-293.
3. Nieborowska-Skorska M., Wasik M., Slupianek A., Salomoni P., Kitamura T., Calabretta B., Skorski T. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J. Exp. Med. 1999, 189:1229-4122.
4. Sillaber C., Gesbert F., Frank D., Sattler M., Griffin J. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood 2000, 95:2118-2125.
5. Sonoyama J., Matsumura I., Ezoe S., Satoh Y., Zhang X., Kataoka Y., Takai E., Mizuk I.M., Machii T., Wakao H., Kanakura Y. Functional cooperation among Ras, STAT5, and phosphatidylinositol 3-kinase is required for full oncogenic activities of BCR/ABL in K562 cells. J. Biol. Chem. 2002, 277:8076-8082.
6. Hazlehurst L., Bewry N., Nair R., Pinilla-Ibarz J. Signaling networks associated with BCR-ABL-dependent transformation. Cancer Control 2009, 16:100-107.
7. Druker B., Tamura S., Buchdunger E., Ohno S., Segal G., Fanning S., Zimmermann J., Lydon N. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 1996, 2:561-566.
8. Kantarjian H., Cortes J., O'Brien S., Giles F., Garcia-Manero G., Faderl S., Thomas D., Jeha S., Rios M., Letvak L., Bochinski K., Arlinghaus R., Talpaz M. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood 2003, 101:97-100.
9. Lee F., Fandi A., Voi M. Overcoming kinase resistance in chronic myeloid leukemia. Int. J. Biochem. Cell Biol. 2008, 40:334-343.
10. Shah N., Nicoll J., Nagar B., Gorre M., Paquette R., Kuriyan J., Sawyers C. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cells 2002, 2:117-125.
11. Redaelli S., Piazza R., Rostagno R., Magistroni V., Perini P., Marega M., Gambacorti-Passerini C., Boschelli F. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J. Clin. Oncol. 2009, 27:469-471.
12. Carter T., Wodicka L., Shah N., Velasco A., Fabian M., Treiber D., Milanov Z., Atteridge C., Biggs W.R., Edeen P., Floyd M., Ford J., Grotzfeld R., Herrgard S., Insko D., Mehta S., Patel H., Pao W., Sawyers C., Varmus H., Zarrinkar P., Lockhart D. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc. Natl. Acad. Sci. USA 2005, 102:11011-11016.
13. Zhang H., Trachootham D., Lu W., Carew J., Giles F., Keating M., Arlinghaus R., Huang P. Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism. Leukemia 2008, 22:1191-1199.
14. Zhang J., Adria F., Jahnke W., Cowan-Jacob S., Li A., Iacob R., Sim T., Powers J., Dierks C., Sun F., Guo G., Ding Q., Okram B., Choi Y., Wojciechowski A., Deng X., Liu G., Fendrich G., Strauss A., Vajpai N., Grzesiek S., Tuntland T., Liu Y., Bursulaya B., Azam M., Manley P., Engen J., Daley J., Warmuth M., Gray N. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 2010, 463:501-506.
15. Hussain M., Kotz H., Minasian L., Premkumar A., Sarosy G., Reed E., Zhai S., Steinberg S., Raggio M., Oliver V.K., Figg W., Kohn E. Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer. J. Clin. Oncol. 2003, 21:4356-4363.
16. Alessandro R., Fontana S., Giordano M., Corrado C., Colomba P., Flugy A., Santoro A., Kohn E., De Leo G. Effects of carboxyamidotriazole on in vitro models of imatinib-resistant chronic myeloid leukemia. J. Cell. Physiol. 2008, 215:111-121.
17. Nathan C. Specificity of a third kind: reactive oxygen and nitrogen intermediates in cell signaling. J. Clin. Invest. 2003, 111:769-778.
18. Zhang Y., Soboloff J., Zhu Z., Berger S. Inhibition of Ca2+ influx is required for mitochondrial reactive oxygen species-induced endoplasmic reticulum Ca2+ depletion and cell death in leukemia cells. Mol. Pharmacol. 2006, 70:1424-1434.
19. Trachootham D., Alexandre J., Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat. Rev. Drug Discov. 2009, 8:579-591.
20. Feng R., Ni H., Wang S., Tourkova I., Shurin M., Harada H., Yin X. Cyanidin-3-rutinoside, a natural polyphenol antioxidant, selectively kills leukemic cells by induction of oxidative stress. J. Biol. Chem. 2007, 282:13468-13476.
21. Xiao D., Powolny A., Singh S. Benzyl isothiocyanate targets mitochondrial respiratory chain to trigger reactive oxygen species-dependent apoptosis in human breast cancer cells. J. Biol. Chem. 2008, 283:30151-30163.
22. Zhang R., Humphreys I., Sahu R., Shi Y., Srivastava S. In vitro and in vivo induction of apoptosis by capsaicin in pancreatic cancer cells is mediated through ROS generation and mitochondrial death pathway. Apoptosis 2008, 13:1465-1478.
23. Parreno M., Casanova I., Cespedes M., Vaque J., Pavon M., Leon J., Mangues R. Bobel-24 and derivatives induce caspase-independent death in pancreatic cancer regardless of apoptotic resistance. Cancer Res. 2008, 68:6313-6323.
24. Parreno M., Vaque J., Casanova I., Frade P., Cespedes M., Pavon M., Molins A., Camacho M., Vila L., Nomdedeu J., Mangues R., Leon J. Novel triiodophenol derivatives induce caspase independent mitochondrial cell death in leukemia cells inhibited by Myc. Mol. Cancer Ther. 2006, 5:1166-1175.
25. Fontana S., Alessandro R., Barranca M., Giordano M., Corrado C., Zanella-Cleon I., Becchi M., Kohn E., De Leo G. Comparative proteome profiling and functional analysis of chronic myelogenous leukemia cell lines. J. Proteome Res. 2008, 6:4330-4342.
26. Kantarjian H., Giles F., Wunderle L., Bhalla K., O'Brien S., Wassmann B., Tanaka C., Manley P., Rae P., Mietlowski W., Bochinski K., Hochhaus A., Griffin J., Hoelzer D., Albitar M., Dugan M., Cortes J., Alland L., Ottmann O. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. New Engl. J. Med. 2006, 354:2542-2551.
27. Puttini M., Coluccia A., Boschelli F., Cleris L., Marchesi E., Donella-Deana A., Ahmed S., Redaelli S., Piazza R., Magistroni V., Andreoni F., Scapozza L., Formelli F., Gambacorti-Passerini C. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res. 2006, 66:11314-11322.
28. O'Hare T., Walters D., Stoffregen E., Jia T., Manley P., Mestan J., Cowan-Jacob S., Lee F., Heinrich M., Deininger M., Druker B. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005, 65:4500-4505.
29. Quintas-Cardama A., Kantarjian H., Jones D., Nicaise C., O'Brien S., Giles F., Talpaz M., Cortes J. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood 2007, 109:497-499.
30. von Bubnoff N., Schneller F., Peschel C., Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 2002, 359:487-491.
31. Ramirez P., DiPersio J. Therapy options in imatinib failures. The Oncologist 2008, 13:424-434.
32. Hu Y., Rosen D., Zhou Y., Feng L., Yang G., Liu J., Huang P. Mitochondrial manganese-superoxide dismutase expression in ovarian cancer: role in cell proliferation and response to oxidative stress. J. Biol. Chem. 2005, 280:39485-39492.
33. Radisky D., Levy D., Littlepage L., Liu H., Nelson C., Fata J., Leake D., Godden E., Albertson D., Nieto M., Werb Z., Bissell M. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 2005, 436:123-127.
34. Irani K., Xia Y., Zweier J., Sollott S., Der C., Fearon E., Sundaresan M., Finkel T., Goldschmidt-Clermont P. Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science 1997, 275:1649-1652.
35. Sattler M., Verma S., Shrikhande G., Byrne C., Pride Y., Winkler T., Greenfield E., Salgia R., Griffin J. The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J. Biol. Chem. 2000, 275:24273-24278.
36. Vafa O., Wade M., Kern S., Beeche M., Pandita T., Hampton G., Wahl G. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol. Cell. 2002, 9:1031-1044.
37. Pelicano H., Carney D., Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist. Update 2004, 7:97-110.
38. Pelicano H., Feng L., Zhou Y., Carew J., Hileman E., Plunkett W., Keating M., Huang P. Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J. Biol. Chem. 2003, 278:37832-37839.
39. Koptyra M., Falinski R., Nowicki M., Stoklosa T., Majsterek I., Nieborowska-Skorska M., Blasiak J., Skorski T. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 2006, 108:319-327.
40. Trachootham D., Zhou Y., Zhang H., Demizu Y., Chen Z., Pelicano H., Chiao P., Achanta G., Arlinghaus R., Liu J., Huang P. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cells 2006, 10:241-252.
41. Su C., Lin J., Li T., Chung J., Yang J., Ip S., Lin W., Chen G. Curcumin-induced apoptosis of human colon cancer colo 205 cells through the production of ROS, Ca2+ and the activation of caspase-3. Anticancer Res. 2006, 26:4379-4389.
42. Ciarcia R., D'Angelo D., Pacilio C., Pagnini D., Galdiero M., Fiorito F., Damiano S., Mattioli E., Lucchetti C., Florio S., Giordano A. Dysregulated calcium homeostasis and oxidative stress in chronic Myeloid leukemia (CML) cells. J. Cell. Physiol. 2010, 224:443-453.
43. Hong S., Dawson T., Dawson V. Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. Trends Pharmacol. Sci. 2004, 25:259-264.